Tandem Diabetes Care (TNDM) Competitors $35.91 +2.64 (+7.94%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TNDM vs. GKOS, BLCO, INSP, PRCT, AXNX, NVCR, NVST, NARI, IRTC, and LIVNShould you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Tandem Diabetes Care vs. Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Glaukos (NYSE:GKOS) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership. Do insiders & institutionals have more ownership in GKOS or TNDM? 99.0% of Glaukos shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, GKOS or TNDM? Glaukos has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Which has better valuation and earnings, GKOS or TNDM? Glaukos has higher earnings, but lower revenue than Tandem Diabetes Care. Glaukos is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$360.35M23.09-$134.66M-$3.02-49.96Tandem Diabetes Care$854.35M2.76-$222.61M-$1.93-18.61 Is GKOS or TNDM more profitable? Tandem Diabetes Care has a net margin of -14.84% compared to Glaukos' net margin of -42.43%. Glaukos' return on equity of -18.99% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-42.43% -18.99% -11.47% Tandem Diabetes Care -14.84%-44.19%-11.99% Does the MarketBeat Community prefer GKOS or TNDM? Tandem Diabetes Care received 139 more outperform votes than Glaukos when rated by MarketBeat users. However, 64.77% of users gave Glaukos an outperform vote while only 61.28% of users gave Tandem Diabetes Care an outperform vote. CompanyUnderperformOutperformGlaukosOutperform Votes44564.77% Underperform Votes24235.23% Tandem Diabetes CareOutperform Votes58461.28% Underperform Votes36938.72% Does the media favor GKOS or TNDM? In the previous week, Glaukos had 11 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 13 mentions for Glaukos and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.59 beat Glaukos' score of 0.96 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend GKOS or TNDM? Glaukos presently has a consensus price target of $145.92, suggesting a potential downside of 3.29%. Tandem Diabetes Care has a consensus price target of $53.81, suggesting a potential upside of 49.85%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85Tandem Diabetes Care 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryGlaukos beats Tandem Diabetes Care on 10 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Tandem Diabetes Care News Delivered to You Automatically Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNDM vs. The Competition Export to ExcelMetricTandem Diabetes CareSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.36B$4.34B$5.12B$9.07BDividend YieldN/A41.46%4.91%4.22%P/E Ratio-18.6125.3791.3417.19Price / Sales2.7645.681,116.59116.80Price / CashN/A43.4542.6437.86Price / Book7.477.364.794.78Net Income-$222.61M$13.64M$120.07M$225.60M7 Day Performance9.95%-2.80%-1.89%-1.24%1 Month Performance16.82%0.56%11.45%3.36%1 Year Performance22.31%41.87%30.61%16.58% Tandem Diabetes Care Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNDMTandem Diabetes Care4.6299 of 5 stars$35.91+7.9%$53.81+49.9%+30.3%$2.36B$854.35M-18.612,400Positive NewsHigh Trading VolumeGKOSGlaukos4.115 of 5 stars$144.20+3.8%$143.17-0.7%+89.5%$7.95B$360.35M-46.00780Analyst ForecastShort Interest ↓BLCOBausch + Lomb3.0993 of 5 stars$18.61+0.1%$20.58+10.6%+16.9%$6.55B$4.68B-17.7113,300INSPInspire Medical Systems4.6549 of 5 stars$188.38+0.3%$233.58+24.0%+1.7%$5.65B$755.59M176.781,011Positive NewsPRCTPROCEPT BioRobotics2.7844 of 5 stars$90.19+1.1%$97.86+8.5%+102.9%$4.71B$136.19M0.00626Positive NewsAXNXAxonics1.4327 of 5 stars$70.98+0.8%$71.00+0.0%+20.9%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.7422 of 5 stars$32.91-1.5%$32.67-0.7%+138.4%$3.56B$577.74M-23.861,453NVSTEnvista3.9012 of 5 stars$19.56+0.5%$20.65+5.6%-21.1%$3.37B$2.50B-2.5112,800NARIInari Medical3.3152 of 5 stars$55.67+0.1%$58.89+5.8%-11.9%$3.26B$574.50M-41.181,300Analyst ForecastInsider TradeIRTCiRhythm Technologies3.2186 of 5 stars$90.08+4.2%$107.82+19.7%-14.3%$2.82B$492.68M-17.782,000Analyst ForecastGap DownLIVNLivaNova3.5889 of 5 stars$50.01-2.9%$69.17+38.3%-4.4%$2.72B$1.24B122.622,900Analyst UpgradePositive News Related Companies and Tools Related Companies GKOS Alternatives BLCO Alternatives INSP Alternatives PRCT Alternatives AXNX Alternatives NVCR Alternatives NVST Alternatives NARI Alternatives IRTC Alternatives LIVN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNDM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tandem Diabetes Care With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TNDM Stock Alerts